PUNCH03: Preliminary results from a phase II study of disitamab vedotin combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in Her2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Zongren Wang, Bin Huang, Cheng Luo, Yukun Wu, Jiahao Lei, Junxing Chen
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162508928
Cites:
Cited by:
Related to: